Lupin Ltd Q2 FY2023 Concall Summary

Key Takeaways

• U.S. recovery drives the beat: Revenue bounced back after a one-time Q1 correction, with the respiratory franchise gaining share and newly launched Suprep beginning to contribute.
• Margins inflected, but the real step-up waits on launches: Cost optimization and lower penalties lifted EBITDA margin, yet management says reaching 16%+ depends on material approvals like Spiriva.
• Spiriva is the make-or-break catalyst: The company has responded to all FDA queries and filed for priority review, with a decision expected in weeks; its approval unlocks a guided exit margin of 16% to 18%.
• India growth is sub-par but a fix is in motion: Growth trailed the market due to diabetes portfolio headwinds; management is adding 850 sales representatives and expects a return to double-digit growth next year.
• What to watch next quarter: The Spiriva TAD date and any plant inspection news, the pace of Suprep’s ramp, and whether the India sales force expansion begins to close the growth gap.

U.S. Business: Recovery and the Respiratory Pivot

• Q1 drag reversed: The U.S. business normalized after a one-time shelf stock adjustment and other write-offs depressed Q1; oral solids price erosion was reasonable, not double-digit.
• Respiratory franchise scaling: The segment became a larger part of the business and contributed to both revenue and profitability growth; the closed acquisition of Sunovion brands Brovana and Xopenex further enhances the position.
• Suprep launch: Launched in September with a small Q2 contribution; more material revenue is expected in Q3 and Q4.
• Failure-to-supply penalties receding: Penalties dropped to under \$2 million this quarter from \$4 million last quarter, alongside freight cost savings, reflecting improved service levels from the Somerset plant now at 98% plus.
• Flu season tailwind emerging: An uptick in anti-infectives and Tamiflu appeared in Q2; API purchase orders for cephalosporins also signal a pickup, with management expecting a stronger season than recent years.

Vinita Gupta: "While we had hoped to get an approval by now, we are close. We have responded to all the queries the agency had raised and are working closely with the FDA to get approval by our eligible launch date. We will know more in the next few weeks..."

The Spiriva Catalyst and Launch Pipeline

• Spiriva timeline: All FDA queries were answered fully within October; a priority review was filed and the TAD date is expected in November, which will indicate whether a plant inspection is required.
• Market opportunity: Management views Spiriva as a substantial contributor for FY24 with significant runway, noting that a lower-priced generic can sometimes recapture share even when a brand shifts to a new dosage form.
• Near-term launches with exclusivity: Darunavir (first-to-file tablet, expected Q1 FY24), Diazepam Gel (next 3 to 6 months), and Nascobal Nasal Spray (Q1 or Q2 next fiscal) all carry exclusivity or first-to-market positions that support profitable growth.
• Dulera status: Received a CRL; the company responded recently and expects to learn in the next couple of months whether the agency is satisfied or more work is needed.
• Biosimilars timing: Pegfilgrastim’s PFS was inspected by the FDA in recent weeks; launch is targeted in the next 6 to 12 months, though significant price erosion is being tracked and the go-to-market model (partner vs. institutional sales force) is still under evaluation.

Vinita Gupta: "But really to get to that 16% level plus, which we are working towards, we need material launches like Spiriva."

Margin Trajectory: Cost-Out Now, Launches Later

• Q2 margin drivers: Gross margin improved sequentially because of the absence of the Q1 shelf stock adjustment, freight cost optimization (both mix and rate), lower write-offs, and a better product mix; price erosion was well contained.
• Cost initiatives underway: Direct cost actions include alternate vendor development, routes to synthesis, workforce optimization at factories and R&D, footprint rationalization, sales force productivity, and freight mode optimization; all are moving in the right direction and are expected to contribute to EBITDA margin improvement over the next year.
• Employee cost reduction: Workforce planning at the factory level delivered savings, though a shift of certain incentives to the sales force in India offset the visible reduction in the employee cost line; more reduction is expected in Q3 and Q4.
• Sequential path: Margins are expected to improve quarter after quarter, reaching 12% to 13% even without new launches; the exit Q4 FY23 EBITDA margin is guided at 16% to 18%, contingent on larger products like Spiriva.
• Beyond FY23: If Spiriva arrives by fiscal year-end and cost initiatives deliver, margin next year should be definitely better than 16%, potentially moving to the high teens; management sees at least 3 interesting U.S. products launching next year to support a return toward 18% to 20%.

Ramesh Swaminathan: "If there's going to be a function of larger products, Sameer, so it could be anywhere between 16% to 18% range, at the lowest, it could be 16%, at the highest level, it could be 18%, which would be the exit run rate in the fourth quarter."

India Business: Fixing Sub-Par Growth

• Growth below market: India growth in Q2 and H1 trailed the market primarily due to the loss of Cidmus from the cardiovascular portfolio and generalisation in gliptins; excluding the diabetes portfolio, India business grew ahead of the market.
• Therapy-area mix: Respiratory and cardiac growth was in line with the market; GI and women’s health grew well above market; diabetes contributed only 2 percentage points of growth while cardiac improved to roughly 10%.
• Sales force expansion: The company is adding 850 representatives by fiscal year-end and launching at least 4 new divisions, an investment management calls material for returning India to double-digit growth.
• Recovery timeline: India business is expected to return to double-digit growth next year, driven by chronic areas like respiratory, cardiac, and GI, even as diabetes remains suppressed.
• In-licensed portfolio headwind: In-licensed products currently represent 16% of the India portfolio; this will progressively decline over the next couple of years as exclusivities lapse, with growth from newer products and the in-line portfolio expected to fill the gap.

Nilesh Gupta: "We should be back to the double-digit growth next year. So, I think diabetes will still continue to be suppressed even next year, but on the back of growth on the other chronic areas like respiratory, on the cardiac segment itself, even other segments like GI and the like, we certainly would get back to double-digit growth."

Other Markets and Portfolio Developments

• Other developed markets: Australia was probably the fastest-growing part of the business in Q2, driven by the Southern Cross integration and products like Fostair; Canada, Germany, and the U.K. also performed well; collectively these markets are roughly 10% of revenues.
• Emerging markets: Mexico delivered strong local-currency growth; Latin America, South Africa, and the Philippines grew double-digit, and the business is profitable at an EBITDA margin well above the company average.
• Fostair expansion: Market share in the U.K. ramped to double digits; launch into additional markets is expected in the last quarter of the fiscal year based on a launch date agreement.
• Sunovion acquisition economics: The Brovana and Xopenex acquisition is EPS-accretive in year 1; Brovana revenues are expected to decline with multiple generic competitors while retaining residual brand revenue; Xopenex is seen as a stable opportunity given the scale and clinical study requirements for generic approval, and management will evaluate promoting it with small-scale investment.
• NCE strategy reset: The NCE team was scaled down and the burn reduced very significantly; the primary investment going forward is clinical development of 5 oncology assets in Phase I.
• Respiratory pipeline build: The company expects to file 1 DPI or SMI product in the next year, with a couple more the year after; MDI products are expected to be filed in the next couple of years.

Vinita Gupta: "When you look at the inhalation pipeline, when you look at the complex injectables pipeline, when you look at our biosimilars pipeline, there's significant potential in all developed markets."

Regulatory and Operational Updates

• FDA clearances: Warning letters at Goa and Somerset were cleared; successful inspections were completed at Ankleshwar and Nagpur.
• Tarapur warning letter: Received during the quarter; management clarified to the FDA that it pertains only to specific products discontinued over the last couple of years; the FDA acknowledged the clarification; supplies are continuing with no disruption anticipated and no meaningful pending approvals from the site.
• Somerset plant turnaround: Compliance issues are behind the plant; service levels are at 98% plus; failure-to-supply penalties are down significantly and plant efficiency has improved materially.
• Tax rate: The high effective rate of 31% to 34% reflects loss-making subsidiaries in various regions; the full-year rate is expected to decline, with Q4 potentially in line with normal rates; over the next 2 to 3 years, tax rates are expected to come down as India rates fall and profitability returns in other regions.
• R&D spend: Expected to remain stable at current levels; Q3 and Q4 will see a reduction from the NCE scale-down, with no material increase anticipated; investment is concentrated in inhalation, injectables, biosimilars, and a steady portfolio of oral solids and ophthalmics.

Guidance & Commitments

Key Metrics